建龍微納(688357.SH):決定將“吸附材料產業園項目(三期)”的建設期延至2021年12月
格隆匯 11 月 9日丨建龍微納(688357.SH)公佈,公司於2020年11月9日召開第二屆董事會第三十七次會議、第二屆監事會第十五次會議,分別審議通過《關於延長募投項目“吸附材料產業園項目(三期)”建設期的議案》,綜合考慮當前募集資金投資項目(“募投項目”)的實施進度等因素,公司決定將募投項目“吸附材料產業園項目(三期)”的建設期延長至2021年12月。
獨立董事對該事項發表了明確同意的獨立意見,保薦機構中天國富證券有限公司(“中天國富證券”)對該事項出具了明確的核查意見。該事項無需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.